Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT01341600 · ClinicalTrials.gov registry record · NA
Clopidogrel Pharmacogenetics (PGX) Bench to Bedside
A NA study of Metabolism of Clopidogrel, sponsored by University of Maryland, Baltimore.
- Completed
- Registry status
- NA
- Development phase
- 18
- Enrollment target
- 1
- Study location
NCT01341600 is a NA study of Metabolism of Clopidogrel that has completed, run by University of Maryland, Baltimore. The registered enrollment target is 18 participants. The trial reports 1 study location across 1 state.
The verdict
NCT01341600, a NA study of Metabolism of Clopidogrel, has completed, sponsored by University of Maryland, Baltimore.
- COMPLETED
- Registry status
- NA
- Development phase
- 18 participants
- Enrollment target
- 1
- Study location
Study Summary
Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug. The variation in treatment response may be linked to genetics. This study will examine the effects of clopidogrel in a population in which sequencing for certain genes has been performed in order to determine the role that genes play in the response to various clopidogrel maintenance doses.
Conditions Studied
Interventions
- DRUG Clopidogrel
- DRUG Omeprazole/Clopidogrel
Study Locations (1)
Pennsylvania
- Amish Research Clinic - Lancaster
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18 participants |
| Start Date | 2010-07 |
| Est. Completion | 2011-05 |
| Phase | NA |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT01341600
The ClinicalTrials.gov registry entry for NCT01341600 describes a study currently listed as completed, categorized as NA. The registered enrollment target is 18 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is University of Maryland, Baltimore, which has 560 total studies on file at ClinicalTrials.gov.
The record links to 1 condition, with Metabolism of Clopidogrel appearing as the primary indexed condition, and to 2 interventions - of which Clopidogrel is the first listed.
NCT01341600 reports 1 study location spanning 1 distinct geographic area - top geographies include Pennsylvania.
Frequently Asked Questions
What is clinical trial NCT01341600 about?
NCT01341600 is a clinical study titled "Clopidogrel Pharmacogenetics (PGX) Bench to Bedside". Clopidogrel (also known as Plavix) is used commonly in patients to prevent heart attacks and conditions caused by blood clots. Although clopidogrel works in many individuals, some people do not respond as well to this drug. The variation in treatment response may be linked to genetics. This study wi...
What is the current status of trial NCT01341600?
This trial is currently completed. It is a NA study. The enrollment target is 18 participants. The study started on 2010-07. Estimated completion is 2011-05.
What conditions does trial NCT01341600 study?
This clinical trial studies the following conditions: Metabolism of Clopidogrel.
What interventions are being tested in trial NCT01341600?
The interventions under investigation include: Clopidogrel (DRUG), Omeprazole/Clopidogrel (DRUG).
Who is sponsoring clinical trial NCT01341600?
This trial is sponsored by University of Maryland, Baltimore, which has 560 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT01341600 being conducted?
This trial has 1 study location across Pennsylvania. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.